54459-33-5

Upstream product

• 117705-67-6 1-(2,4-dimethoxyphenyl)-1-butanol 
• 109-69-3 n-Butyl chloride 
• 20469-63-0 1-iodo-2,4-dimethoxybenzene 
• 151-10-0 1,3-Dimethoxybenzene 
• 6703-00-0 1-(2,4-dimethoxyphenyl)butan-1-one 
• 96898-01-0 (2,4-dimethoxyphenyl)butene 
• 613-45-6 2,4-Dimethoxybenzaldehyde 

Downstream Products

• 117690-82-1 5-butyl-2,4-dimethoxyacetophenone 
• 117690-69-4 4-(4-cyanobutoxy)-5-butyl-2-hydroxyacetophenone 
• 81468-73-7 1-(5-butyl-2,4-dihydroxyphenyl)ethan-1-one 
• 96897-99-3 3-butyl-2,6-dimethoxybenzoic acid 
• 856807-99-3 4-(5-butyl-2,4-dimethoxy-phenyl)-4-oxo-butyric acid 

Relevant academic research and scientific papers

Pd-catalyzed cross-electrophile Coupling/C-H alkylation reaction enabled by a mediator generatedviaC(sp3)-H activation

Transition-metal-catalyzed cross-electrophile C(sp2)-(sp3) coupling and C-H alkylation reactions represent two efficient methods for the incorporation of an alkyl group into aromatic rings. Herein, we report a Pd-catalyzed cascade cross-electrophile coupling and C-H alkylation reaction of 2-iodo-alkoxylarenes with alkyl chlorides. Methoxy and benzyloxy groups, which are ubiquitous functional groups and common protecting groups, were utilized as crucial mediatorsviaprimary or secondary C(sp3)-H activation. The reaction provides an innovative and convenient access for the synthesis of alkylated phenol derivatives, which are widely found in bioactive compounds and organic functional materials.

Leukotriene B4 Receptor Antagonists: The LY255283 Series of Hydroxyacetophenones

A series of hydroxyacetophenones was prepared for evaluation as leukotriene B4 (LTB4) receptor antagonists, culminating in 1-oxy>phenyl>ethanone (compound 35, LY255283).Using an assay for inhibition of specific LTB4 binding to human PMN, we found that substitution of a nonpolar substituent in the 5-position was required for activity.Best activity was realized with hydrogen in the 3-position, hydroxyl in the 2-position, short chain alkyl ketone in the 1-position, and a six- or eight-carbon chain linking the oxygen in the 4-position with an unsaturated terminal function.Compound 35, having an IC50 of 87 nM in the binding assay, was chosen for further preclinical evaluation.

ANTI-INFLAMMATORY AGENTS

This invention provides benzene derivatives, pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.

Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamides

A series of substituted 6-methoxysalicylamides were synthesized from their corresponding 2,6-dimethoxybenzamides by demethylation of one methoxy group with boron tribromide. Substituted 6-methoxysalicylamides having a lipophilic aromatic substituent in the 3-position para with respect to the methoxy group, e.g. a bromo or an iodo atom or an ethyl or a propyl group, and having an (S)-N-(1-alkyl-2-pyrrolidinyl)methyl moiety as the side chain were found to be potent blockers of [3H]spiperone binding in vitro and potent inhibitors of the apomorphine syndrome in the rat. Similar to remoxipride but in contrast to haloperidol, some of the substituted salicylamides show a 10-20 fold separation between the dose that inhibits hyperactivity and that which inhibits stereotypy. It was concluded that, besides the requirement of a lipophilic substitutent in the position para to the methoxy group for antidopamine activity in vivo, the formation of a coplanar six-membered pseudoring involving the amide moiety and the methoxy group is a structural requirement for activity in vitro.